Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vaccination

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,004 result(s) found for: Vaccination. Displaying page 47 of 101.
    «« First « Previous 43  44  45  46  47  48  49  50  51  Next» Last»»
    EudraCT Number: 2014-005183-15 Sponsor Protocol Number: CSLCT-CAL-09-60 Start Date*: 2015-01-09
    Sponsor Name:CSL Limited
    Full Title: A Phase II, Multicentre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children Aged >= 6 Months ...
    Medical condition: Influenza, human.
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-001303-34 Sponsor Protocol Number: 111295 Start Date*: 2008-06-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase I/II, randomized, single blind, controlled study in adults aged 18-60 years to evaluate the immunogenicity, safety and reactogenicity of an adjuvanted influenza vaccine candidate (GSK 21151...
    Medical condition: Immunization of healthy adults aged 18 to 60 years against influenza
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-001714-26 Sponsor Protocol Number: CYD29 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril®) Administered Concomitantly with Tetravalent Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and Peru
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-005013-23 Sponsor Protocol Number: M37P2E1 Start Date*: 2014-11-25
    Sponsor Name:Novartis Vaccines and Diagnostics
    Full Title: A Phase III Open Label, Multi-Center Pediatric Study in China Comparing a Booster Dose of Vaxem™ Hib to HIBERIX®
    Medical condition: Meningitis, epiglottitis, pneumonia, arthritis caused by Haemophilus influenzae type b.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-002360-28 Sponsor Protocol Number: 104886 Start Date*: 2005-09-13
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open, randomized phase I/II study to demonstrate the non inferiority in term of cellular mediated immune response between GlaxoSmithKline Biologicals influenza candidate vaccines containing vari...
    Medical condition: Immunisation against influenza disease in adults aged 18-40 years and elderly population aged over 65 years (>65 years)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017688-40 Sponsor Protocol Number: GID34 Start Date*: 2010-04-16
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intradermal Route)
    Medical condition: Vaccination of adults up to 59 years of age and elderly of 60 years of age and over with inactivated split-virion influenza vaccine administered by the intraderma route
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004302-74 Sponsor Protocol Number: StaMen Start Date*: 2007-05-22
    Sponsor Name:Health Protection Agency
    Full Title: A Phase IV, single group study to evaluate the immunogenicity and safety in UK laboratory workers of a licensed Hib and meningococcal C conjugate combined vaccine (Menitorix)
    Medical condition: Investigating the immunogenicity and safety of a licensed Hib and meninigococcal C combined conjugate vaccine (Menitorix) in laboratory workers.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10027276 Meningococcal meningitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001711-40 Sponsor Protocol Number: CYD24 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003479-36 Sponsor Protocol Number: 115992 Start Date*: 2015-05-20
    Sponsor Name: GlaxoSmithKline Biologicals
    Full Title: A phase III, controlled, partially-blind study to assess the reactogenicity, safety and immunogenicity of GSK Biologicals' 10-valent pneumococcal polysaccharide and non-typeable Haemophilus influen...
    Medical condition: Healthy volunteers (Two-dose primary vaccination of healthy infants 6-12 weeks of age at the time of first vaccination against S. pneumoniae and H. influenzae according to a 2 months interval sched...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10042197 Streptococcus pneumoniae septicaemia LLT
    18.0 100000004862 10042195 Streptococcus pneumoniae pneumonia LLT
    18.0 100000004862 10054642 Streptococcus pneumoniae septicemia LLT
    18.0 100000004862 10035648 Pneumococcal pneumonia [Streptococcus pneumoniae pneumonia] LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004518-40 Sponsor Protocol Number: PCV13-HIV2011 Start Date*: 2011-10-25
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: Serological response to antipneumococcal vaccination and consequent impact on Streptococcus pneumoniae nasal carriage in HIV positive adults: a prospective study using 13-valent conjugate vaccine
    Medical condition: HIV positive adults with out previous PPV23 or PCV7 vaccination
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10035652 Pneumococcus infection in conditions classified elsewhere and of unspecified site LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000110-21 Sponsor Protocol Number: BT959 Start Date*: 2006-11-21
    Sponsor Name:Biotest AG
    Full Title: An open, randomised parallel study investigating efficacy and safety of the human hepatitis B immunoglobulin BT088 after subcutaneous or intramuscular application for perinatal prophylaxis in infan...
    Medical condition: Healthy mature male and female neonates of gestational week ≥ 37+0 with indication for hepatitis B prophylaxis due to a HBsAg positive mother.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10054130 Hepatitis B immunisation LLT
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005650-35 Sponsor Protocol Number: CHDR1503 Start Date*: 2016-04-04
    Sponsor Name:Centre for Human Drug Research
    Full Title: Proof-of-pharmacology clinical trial on a vaccine that elicits a protective humoral immune response against oxidized low density lipoprotein
    Medical condition: Healthy male volunteers
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-002095-18 Sponsor Protocol Number: 107731 Start Date*: 2007-03-20
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II randomized, double-blind (observer blind), adjuvant justification study of RTS,S/AS01B and RTS,S/AS02A, candidate malaria vaccines, administered according to a 0, 1, 2 months schedule in...
    Medical condition: Malaria disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007876-41 Sponsor Protocol Number: 111567 Start Date*: 2008-03-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, randomized, open study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ Hepatitis B vaccine (Engerix-B™) when co-administered with GlaxoSmithKline Biologicals...
    Medical condition: Cervarix™ is indicated for the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017690-38 Sponsor Protocol Number: GRT90 Start Date*: 2010-04-06
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route)
    Medical condition: Vaccination of adults up to 60 years of age an elderly of 61 years of age and over with inactivated split-virion influenza vaccine administerd by intramuscular route.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-001555-38 Sponsor Protocol Number: 104745 Start Date*: 2005-06-14
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Open Immunization Study to Determine the Reactogenicity and Immunogenicity of Fluarix/ Influsplit SSW 2005/2006 in Persons as of 18 Years of Age
    Medical condition: Immunization against Influenza in healthy male and female subjects aged over 18 years
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004288-37 Sponsor Protocol Number: NOR-213 Start Date*: 2017-03-15
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects who have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
    Medical condition: Long-Term Immunogenicity Follow-up Trial of adult and Elderly Subjects who have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000022894 10062371 Active immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002560-73 Sponsor Protocol Number: SWITCH_ON Start Date*: 2022-09-01
    Sponsor Name:Erasmus MC
    Full Title: SWITCH ON: Analysing the immunogenicity of additional booster vaccinations in healthcare workers.
    Medical condition: To study the necessity to boost healthcare workers (which arre representative for the dutch population) with a COVID vaccin by measuring the immunogenicity at 7 days and 28 days..
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002667-14 Sponsor Protocol Number: UHKT-RLP/2011 Start Date*: 2011-07-19
    Sponsor Name:Institute of Hematology and Blood Transfusion
    Full Title: Effect of vaccination in patients with recurrent respiratory papillomatosis– can we improve the quality of life of these patients?
    Medical condition: Recurrent respiratory papillomatosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023849 Laryngeal papilloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-000548-23 Sponsor Protocol Number: UKE-SARS-COV-2-ST Start Date*: 2021-07-07
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: A multi-center, phase Ib trial to assess the safety, tolerability and immunogenicity of the candidate vaccine MVA-SARS-2-ST in adults
    Medical condition: This study is designed to evaluate the safety, tolerability and reactogenicity of intramuscular dose administrations of: -3 dose levels of the MVA-SARS-2-ST vaccine in healthy SARS-CoV-2 seronegati...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 43  44  45  46  47  48  49  50  51  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 19 08:08:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA